Lawsuit: Birth control mix-up results in 113
Lawsuit: Birth control mix-up results in 113 pregnancies
By MARYCLAIRE DALE
Associated Press
The lawsuit, filed in Philadelphia, is brought against Qualitest Inc., a subsidiary of the Irish drug-maker Endo Pharmaceuticals Inc., but names Patheon as well as Vintage Pharmaceuticals as defendants
PHILADELPHIA (AP) - More than 100 women who blame their pregnancies on errant birth control packaging have joined a negligence lawsuit filed in Philadelphia against several drug companies.
The lawsuit follows a 2011 recall of more than 500,000 blister packs after an Iowa customer found the pills packaged out of order, potentially increasing the chance of getting pregnant.
All but four of the 117 women involved in the lawsuit became pregnant and 94 went on to give birth.
They are now suing Endo Pharmaceuticals Inc. and other companies that made or distributed the pills under various brand names. The women are seeking damages for lost income, medical costs and, in some cases, the cost of raising their children.
A spokeswoman at Endo's U.S. headquarters in Malvern did not immediately return a message Thursday seeking comment.
The lawsuit filed last week in Philadelphia came days after a federal judge in Georgia refused to grant class-action certification to a similar suit filed there.
U.S. District Judge Steve C. Jones noted in his ruling that only 53 of the half-million recalled blister packs had the pills arranged in reverse order in the package. He said that each woman's case was unique - given whether she became pregnant, whether she carried the pregnancy to term, the relevant laws in her state, and whether she kept the package or receipt - and should be weighed individually.
"It is not enough that each class member prove that defendants sold a defective product," Jones wrote. "Each plaintiff must show in an individualized manner which 'physical symptoms' she suffered, her medical history, and whether her use of any allegedly defective product resulted in these physical symptoms or a pregnancy."
The recall involved the brand names Cyclafem, Emoquette, Gildess, Orsythia, Previfem and Tri-Previfem.
Each packet of birth control contains 28 days' worth of pills, with 21 containing hormones that prevent pregnancy and seven placebos pills. Women are supposed to take the pills in order and not mix the placebos with the active pills. The pills are normally color-coded to note the difference.
Laws in some states allow women to sue over the cost of raising a child to age 18, according to lawyer Keith Bodoh of Marietta, Georgia, who filed the Philadelphia lawsuit. Damages in a few states could include the cost of college. But the formula in four states involves the cost of raising a child minus the presumed benefits.
"It's amorphous, what to decide (is) the cost and benefit of rearing a child," Bodoh said this week
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...
Continue Reading
Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...
Continue Reading
A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...
Continue Reading
Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...
Continue Reading
A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...
Continue Reading
A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...
Continue Reading
A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...
Continue Reading
Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...
Continue Reading
By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...
Continue Reading
A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...
Continue Reading
Top 5 Most Recently Viewed Articles
Coca-Cola's Position in Emerging Markets Coca-Cola Co (NYSE: KO) stands as a beacon of growth, with a visionary strategy that highlights both immediate and long-term opportunities. The company has successfully positioned itself in vital markets, particularly in North America and Latin America, which have proven central to its success. According to recent insights from...
Continue Reading
Voda IQ dropped some big news back in 2024 when they appointed Armando Piccinini as their European Sales Director. This guy’s got over twenty years under his belt in aquatic conservation, which they clearly hope will ramp up their sales strategy across Europe. But you gotta wonder—are the numbers behind this move really there? Can Experience Translate to Sales Growth?...
Continue Reading
Magnera Corporation's Conference Participation Announcement Magnera Corporation (NYSE: MAGN) has made an exciting announcement regarding its upcoming participation in a significant financial event. The company is set to be a part of the 2025 Bank of America Leveraged Finance Conference, aimed at fostering connections with top institutional investors. The event will take...
Continue Reading
Exciting Developments in Merck & Co Options Activity Notable investors are expressing strong optimism about Merck & Co. A recent analysis of options trading strategies reveals a wave of activity among traders aiming to capitalize on this potential. Options Trading Overview When reviewing the options history for Merck & Co (NYSE: MRK), we found a total of 33 trades that...
Continue Reading
The Big Play for Cancer Innovation Gilead Sciences Inc. (NASDAQ:GILD) pulled the trigger on a pretty huge acquisition deal, landing Arcellx Inc. (NASDAQ:ACLX) this past Monday for a staggering $115 per share, which gets better with a potential extra $5 per share on a contingent value right. That rings in a hefty total of $7.8 billion—no pocket change, folks. What’s...
Continue Reading